- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- BioSummarAI
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: XRCC1
Gene name: X-ray repair complementing defective repair in Chinese hamster cells 1
HGNC ID: 12828
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | CD80 | 1 hits |
| 2 | CSF2 | 1 hits |
| 3 | HLA-A | 1 hits |
| 4 | IL2 | 1 hits |
| 5 | IL7 | 1 hits |
| 6 | MUC1 | 1 hits |
| 7 | RCA1 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 8872982 | Rates of secretion of granulocyte-macrophage colony stimulating factor (GM-CSF) were measured in 50 primary cell cultures derived from cancerous and normal human kidneys. |
| 2 | 8872982 | Some cultured human renal carcinoma cells (RCC) secreted GM-CSF at levels that occasionally overlapped the levels produced by the GM-CSF gene-modified human RCC vaccine now in phase I trial. |
| 3 | 21068778 | Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. |
| 4 | 21068778 | Therefore, in our clinical study, 10 human leukocyte antigen (HLA)-A(*)0201(+) patients with histologically-confirmed progressive metastatic clear cell RCC were immunized repetitively over 22 weeks with 2.5-40 × 10(6) interleukin (IL)-7/CD80 cotransfected allogeneic HLA-A(*)0201(+) tumor cells (RCC26/IL-7/CD80). |
| 5 | 21068778 | However, vaccination with allogeneic RCC26/IL-7/CD80 tumor cells was not able to induce TH1-polarized immune responses. |
| 6 | 21069322 | This phase II study determined the efficacy and tolerability of TG4010, a cancer vaccine based on a modified vaccinia virus expressing MUC1 and interleukin-2, in combination with cytokines, as first-line therapy in metastatic RCC. |
| 7 | 21069322 | Thirty-seven patients with progressive, MUC1-positive RCC received TG4010 10(8) pfu/inj weekly for 6 weeks, then every 3 weeks until progression, when TG4010 was continued in combination with interferon-α2a and interleukin-2. |
| 8 | 21069322 | Six of 28 patients showed a MUC1 CD4+ T cell proliferative response during therapy. |
| 9 | 21069322 | MUC1-specific CD8+ T cell responses were associated with longer survival. |